
05/06/2023
Targeted synthetic and biologic therapies are recommended as disease-modifying agents for key fibrotic manifestations of systemic sclerosis for the first time in the 2023 update of European Alliance of Associations for Rheumatology recommendations for the treatment of systemic sclerosis.
The update to 2017 recommendations include targeted synthetic and biologic DMARDs for the first time.